Richard I. Eisenstadt - 31 Dec 2021 Form 4 Insider Report for Altimmune, Inc. (ALT)

Role
Chief Financial Officer
Signature
/s/ Richard I. Eisenstadt
Issuer symbol
ALT
Transactions as of
31 Dec 2021
Net transactions value
$0
Form type
4
Filing time
04 Jan 2022, 05:11:23 UTC
Next filing
03 Aug 2022
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ALT Stock Options (option to buy) Award $0 +150,000 $0.000000 150,000 31 Dec 2021 Common Stock, par value $0.0001 150,000 $9.16 Direct F1
transaction ALT Restricted Stock Units Award $0 +50,000 $0.000000 50,000 31 Dec 2021 Common Stock, par value $0.0001 50,000 Direct F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The shares underlying the option become vested and exercisable over four (4) years with 25% of the shares vesting on December 31, 2022, with the remainder vesting in equal monthly installments for the following thirty-six (36) months, subject to the reporting person's continued service on each applicable vesting date.
F2 Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Common Stock, par value $0.0001, when vested.
F3 The RSUs become vested and exercisable over four (4) years with 25% of the shares vesting on December 31, 2022, with the remainder vesting in equal annual installments for the following three (3) years, subject to the reporting person's continued service through the applicable vesting date, and have no expiration date.